Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

66.7%

6 terminated/withdrawn out of 9 trials

Success Rate

25.0%

-61.5% vs industry average

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1

7(77.8%)

Phase 2

1(11.1%)

Phase 3

1(11.1%)

9Total

Phase 1(7)

Phase 2(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT04004442Phase 1Active Not Recruiting

Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma

Role: collaborator

NCT05826015Phase 1Withdrawn

AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer

Role: collaborator

NCT04729608Phase 3Terminated

Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Role: lead

NCT04983407Phase 1Terminated

Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma

Role: lead

NCT04300140Phase 1Terminated

Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Role: lead

NCT03639246Phase 1Completed

Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Role: lead

NCT04042623Phase 2Terminated

Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy

Role: lead

NCT03607955Phase 1Withdrawn

Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy

Role: collaborator

NCT03401528Phase 1Completed

A Phase 1 AVB-S6-500 Safety and Tolerability Study

Role: lead

All 9 trials loaded